Potent, selective inhibitors of protein tyrosine phosphatase 1B

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 11, 2003, Pages 1887-1890

  Xin, Zhili ^a   Oost, Thorsten K ^a   Abad Zapatero, Cele ^a   Hajduk, Philip J ^a   Pei, Zhonghua ^a   Szczepankiewicz, Bruce G ^a   Hutchins, Charles W ^a   Ballaron, Steve J ^a   Stashko, Mike A ^a   Lubben, Tom ^a   Trevillyan, James M ^a   Jirousek, Mike R ^a,b   Liu, Gang ^a  

^a ABBOTT LABORATORIES   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOIC ACID DERIVATIVE; OXALYLARYLAMINOBENZOIC ACID; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG COMPETITION; DRUG CONFORMATION; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

EID: 12444315106     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00302-0     Document Type: Article

References (19)

1. (a) Saltiel A.R., Kahn C.R. Nature. 414:2001;799 (b) Ukkola O., Santaniemi M. J. Intern. Med. 251:2002;467.
2. (a) Saltiel A.R., Kahn C.R. Nature. 414:2001;799 (b) Ukkola O., Santaniemi M. J. Intern. Med. 251:2002;467.
3. Cheng A., Dube N., Gu F., Tremblay M.L. Eur. J. Biochem. 269:2002;1050.
4. (a) Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., Normandin D., Cheng A., Himms-Hagen J., Chan C.C., Ramachandran C., Gresser M.J., Tremblay M.L., Kennedy B.P. Science. 283:1999;1544 (b) Klaman L.D., Boss O., Peroni O.D., Kim J.K., Martino J.L., Zabotny J.M., Moghal N., Lubkin M., Kim Y.-B., Sharpe A.H., Stricker-Krongrad A., Shulman G.I., Neel B.G., Kahn B.B. Mol. Cell. Biol. 20:2000;5479.
5. (a) Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., Normandin D., Cheng A., Himms-Hagen J., Chan C.C., Ramachandran C., Gresser M.J., Tremblay M.L., Kennedy B.P. Science. 283:1999;1544 (b) Klaman L.D., Boss O., Peroni O.D., Kim J.K., Martino J.L., Zabotny J.M., Moghal N., Lubkin M., Kim Y.-B., Sharpe A.H., Stricker-Krongrad A., Shulman G.I., Neel B.G., Kahn B.B. Mol. Cell. Biol. 20:2000;5479.
6. Zinker B.A., Rondinone C.M., Trevillyan J.M., Gum R.J., Clampit J.E., Waring J.F., Xie N., Wilcox D., Jacobson P., Frost L., Kroeger P.E., Reilly R.M., Koterski S., Opgenorth T.J., Ulrich R.G., Crosby S., Butler M., Murray S.F., Mckay R.A., Bhanot S., Monia B.P., Jirousek M.R. Proc. Natl. Acad. Sci. U.S.A. 99:2002;11357.
7. Blaskovich M.A., Kim H.-O. Exp. Opin. Ther. Pat. 12:2002;871.
8. You-Ten K.E., Muise E.S., Itié A., Michaliszyn E., Wagner J., Jothy S., Lapp W.S., Tremblay M.L. J. Exp. Med. 186:1997;683.
9. Puius Y.A., Zhao Y., Sullivan M., Lawrence D.S., Almo S.C., Zhang Z.-Y. Proc. Natl. Acad. Sci. U.S.A. 94:1997;13420.
10. Shen K., Keng Y.F., Wu L., Guo X.L., Lawrence D.S., Zhang Z.-Y. J. Biol. Chem. 276:2001;47311.
11. Liu, G.; Szczepankiewicz, B. G.; Pei, Z.; Janowick, D.; Xin, Z.; Liang, H.; Hadjuk, P. J.; Abad-Zapatero, C.; Hutchins, C. W.; Fesik, S. W.; Ballaron, S. J.; Stashko, M. A.; Lubben, T.; Mika, A. K.; Zinker, B. A.; Trevillyan, J. M.; Jirousek, M. R. J. Med. Chem. In press.
12. For in vitro assay protocols, see: Lubben, T.; Clampit, J.; Stashko, M.; Trevillyan, J.; Jirousek, M.R. In Current Protocols in Pharmacology; Enna, S. J., Williams, M., Ferkany, J. W., Kenakin, T., Porsolt, R. D., Sullivan, J. P. Eds.; Wiley: New York, 2001; p 3.8.1.
13. Scherrer R.A., Beatty H.R. J. Org. Chem. 45:1980;2127.
14. Skelakatos G.C., Paganou A., Zervas L. J. Chem. Soc. C. 1966;1191.
15. The purity of the compounds tested exceeds 90% as determined by analytical HPLC.
16. Refined crystallographic coordinates for the structure of PTP1B complexed with compounds 19 have been deposited with the Protein Data Bank (www.rcsb.org) with entry codes 1NZ7.
17. (a) Andersen H.S., Olsen O.H., Iversen L.F., Sorensen A.L.P., Mortensen S.B., Christensen M.S., Branner S., Hansen T.K., Lau J.F., Jeppesen L., Moran E.J., Su J., Bakir F., Judge L., Shahbaz M., Collins T., Vo T., Newman M.J., Ripka W.C., Moller N.P.H. J. Med. Chem. 45:2002;4443 (b) Larsen S.D., Barf T., Liljebris C., May P.D., Ogg D., O'Sullivan T.J., Palazuk B.J., Schostarez H.J., Stevens F.C., Bleasdale J.E. J. Med. Chem. 45:2002;598.
18. (a) Andersen H.S., Olsen O.H., Iversen L.F., Sorensen A.L.P., Mortensen S.B., Christensen M.S., Branner S., Hansen T.K., Lau J.F., Jeppesen L., Moran E.J., Su J., Bakir F., Judge L., Shahbaz M., Collins T., Vo T., Newman M.J., Ripka W.C., Moller N.P.H. J. Med. Chem. 45:2002;4443 (b) Larsen S.D., Barf T., Liljebris C., May P.D., Ogg D., O'Sullivan T.J., Palazuk B.J., Schostarez H.J., Stevens F.C., Bleasdale J.E. J. Med. Chem. 45:2002;598.
19. Co-crystalization of TCPTP with inhibitor has failed due to a multimerization process. See: Iversen L.F., Moller K.B., Pedersen A.K., Peters G.H., Petersen A.S., Andersen H.S., Branner S., Mortensen S.B., Moller N.P.H. J. Biol. Chem. 277:2002;19982.